PL360288A1 - Kompozycje i sposoby polepszania doustnej absorpcji środków przeciwbakteryjnych - Google Patents

Kompozycje i sposoby polepszania doustnej absorpcji środków przeciwbakteryjnych

Info

Publication number
PL360288A1
PL360288A1 PL36028801A PL36028801A PL360288A1 PL 360288 A1 PL360288 A1 PL 360288A1 PL 36028801 A PL36028801 A PL 36028801A PL 36028801 A PL36028801 A PL 36028801A PL 360288 A1 PL360288 A1 PL 360288A1
Authority
PL
Poland
Prior art keywords
methods
biopolymer
compositions
improve
antimicrobial agents
Prior art date
Application number
PL36028801A
Other languages
English (en)
Other versions
PL206492B1 (pl
Inventor
Seung-Ho Choi
Jeoung-Soo Lee
Dennis Keith
Original Assignee
Cubist Pharmaceuticals Inc.
International Health Management Associates Inc.
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/598,089 external-priority patent/US6248360B1/en
Application filed by Cubist Pharmaceuticals Inc., International Health Management Associates Inc., University Of Utah Research Foundation filed Critical Cubist Pharmaceuticals Inc.
Publication of PL360288A1 publication Critical patent/PL360288A1/pl
Publication of PL206492B1 publication Critical patent/PL206492B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL360288A 2000-06-21 2001-06-18 Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny i jej zastosowania PL206492B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/598,089 US6248360B1 (en) 2000-06-21 2000-06-21 Complexes to improve oral absorption of poorly absorbable antibiotics
US82940501A 2001-04-09 2001-04-09
US28397601P 2001-04-16 2001-04-16

Publications (2)

Publication Number Publication Date
PL360288A1 true PL360288A1 (pl) 2004-09-06
PL206492B1 PL206492B1 (pl) 2010-08-31

Family

ID=27403433

Family Applications (2)

Application Number Title Priority Date Filing Date
PL388836A PL218223B1 (pl) 2000-06-21 2001-06-18 Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
PL360288A PL206492B1 (pl) 2000-06-21 2001-06-18 Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny i jej zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL388836A PL218223B1 (pl) 2000-06-21 2001-06-18 Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny

Country Status (16)

Country Link
EP (2) EP2263654B1 (pl)
JP (1) JP4969013B2 (pl)
KR (2) KR20080056308A (pl)
CN (1) CN100358579C (pl)
AT (1) ATE510533T1 (pl)
AU (2) AU2001267011B2 (pl)
BR (1) BR0112393A (pl)
CA (1) CA2413251C (pl)
ES (1) ES2394926T3 (pl)
IL (2) IL153514A0 (pl)
MX (1) MXPA02012670A (pl)
NZ (1) NZ523276A (pl)
PL (2) PL218223B1 (pl)
PT (1) PT1294361E (pl)
UA (1) UA82824C2 (pl)
WO (1) WO2001097851A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726789A1 (en) 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
AU2001259298A1 (en) 2000-05-02 2001-11-12 Advanced Medicine, Inc. Polyacid glycopeptide derivatives
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
AU2002215180A1 (en) * 2000-10-12 2002-04-22 Orchid Chemicals And Pharmaceuticals Limited Beta-lactam antibiotic-polysaccharide complex
ATE303149T1 (de) * 2001-02-27 2005-09-15 Ranbaxy Lab Ltd Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
US7317001B2 (en) 2002-06-06 2008-01-08 Oscient Pharmaceuticals Corporation Use of ramoplanin to treat diseases associated with the use of antibiotics
ITMI20021725A1 (it) * 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
RU2333766C2 (ru) * 2002-11-18 2008-09-20 Вайкьюрон Фармасьютикалз Инк. Способы введения далбаванцина для лечения бактериальных инфекций
CN101130060B (zh) * 2002-11-18 2012-09-05 维克伦制药股份有限公司 含有达巴霉素的医药组合物
RU2275916C1 (ru) * 2004-10-11 2006-05-10 Меграбян Казарос Аршалуйсович Энтеросорбент для выведения тяжелых металлов
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
EP2974718A1 (en) * 2005-04-29 2016-01-20 Cubist Pharmaceuticals, Inc. Therapeutic compositions
US7795207B2 (en) 2005-11-21 2010-09-14 Harald Labischinski Lipopeptide compositions
DE102005056194A1 (de) * 2005-11-21 2007-07-12 Combinature Biopharm Ag Neue Lipopeptid Zusammensetzungen
US9023891B2 (en) 2008-05-29 2015-05-05 Nevada Naturals, Inc. Synergistic antimicrobial agents
RU2607526C2 (ru) * 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
NZ610638A (en) * 2010-11-24 2015-05-29 Melinta Therapeutics Inc Pharmaceutical compositions comprising radezolid
RU2013157188A (ru) * 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
WO2013025783A2 (en) * 2011-08-15 2013-02-21 Gentle Thomas M Water soluble antimicrobial composition
WO2013169231A1 (en) * 2012-05-07 2013-11-14 Nevada Naturals, Inc. Synergistic antimicrobial agents
CN102871996B (zh) * 2012-09-10 2014-12-24 中国医学科学院医药生物技术研究所 一种抗菌药物组合物及其应用
TWI504347B (zh) * 2012-11-23 2015-10-21 Pi Yen Company Ltd Anti-mosquito microcapsule composition, anti-mosquito microcapsule, anti-mosquito spray and anti-mosquito emulsion
CN103230364B (zh) * 2013-05-13 2014-06-11 青岛农业大学 一种头孢噻呋酸长效注射液的制备方法
DE102015100613A1 (de) 2015-01-16 2016-07-21 Andreas Hettich Gmbh & Co. Kg Rotor einer Dualen Zentrifuge
BR112017026245A2 (pt) 2015-06-05 2018-09-11 Firmenich & Cie microcápsulas com alta deposição em superfícies
KR20190005940A (ko) * 2016-05-09 2019-01-16 셀리아 파마슈티칼즈 에이피에스 안정화된 글리코펩티드 항생제 제형
CN106420616A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢曲松钠干混悬剂
CN106420658A (zh) * 2016-09-23 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢他啶胶囊
KR102044934B1 (ko) * 2017-08-11 2019-11-15 서울대학교 산학협력단 카르노스산 내포 환형 아밀로오스 복합체 및 그 제조방법
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
JP7217021B2 (ja) * 2017-09-25 2023-02-02 京都府公立大学法人 ２剤型粘膜下注入用局注液
AU2019278927A1 (en) * 2018-06-01 2020-12-24 Bt Bidco, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
WO2020229369A1 (en) * 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations
WO2023211501A1 (en) * 2022-04-26 2023-11-02 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4297621A (en) 1980-10-02 1981-10-27 Sperry Corporation Cathode ray tube beam deflection amplifier system
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS6067413A (ja) * 1983-09-24 1985-04-17 Kyoto Yakuhin Kogyo Kk 直腸投与用組成物
US4612337A (en) * 1985-05-30 1986-09-16 The Trustees Of Columbia University In The City Of New York Method for preparing infection-resistant materials
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5190748A (en) 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
NZ260933A (en) * 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
US5856474A (en) 1994-04-25 1999-01-05 Biochemie Gesellschaft, M.B.H. Cephalosporin synthesis
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
JP3783993B2 (ja) * 1997-07-24 2006-06-07 エーザイ株式会社 製剤組成物及びその製造方法
US6025352A (en) 1997-09-29 2000-02-15 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
EP1048669A1 (en) 1997-12-16 2000-11-02 Banyu Pharmaceutical Co., Ltd. Carbapenem derivatives
CA2322658C (en) 1998-03-02 2005-04-12 Merck & Co., Inc. Process for synthesizing carbapenem antibiotics
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
US6232306B1 (en) 1998-06-15 2001-05-15 Hoffmann-La Roche Inc. Derivatives of 3-(2-oxo-[1,3′]bipyrrolidinyl-3-ylidenemethyl)-cephams
TWI250160B (en) 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics

Also Published As

Publication number Publication date
MXPA02012670A (es) 2003-10-06
PL218223B1 (pl) 2014-10-31
BR0112393A (pt) 2003-07-08
KR100858945B1 (ko) 2008-09-17
EP2263654B1 (en) 2012-10-10
KR20080056308A (ko) 2008-06-20
PT1294361E (pt) 2011-07-26
HK1058763A1 (zh) 2004-06-04
CN1441668A (zh) 2003-09-10
IL153514A0 (en) 2003-07-06
WO2001097851A3 (en) 2002-05-16
ATE510533T1 (de) 2011-06-15
AU6701101A (en) 2002-01-02
ES2394926T3 (es) 2013-02-06
AU2001267011B2 (en) 2006-02-02
EP2263654A1 (en) 2010-12-22
UA82824C2 (uk) 2008-05-26
NZ523276A (en) 2005-02-25
CA2413251C (en) 2012-06-12
CN100358579C (zh) 2008-01-02
WO2001097851A2 (en) 2001-12-27
EP1294361B1 (en) 2011-05-25
JP4969013B2 (ja) 2012-07-04
CA2413251A1 (en) 2001-12-27
PL206492B1 (pl) 2010-08-31
JP2003535911A (ja) 2003-12-02
HK1152232A1 (en) 2012-02-24
KR20030023877A (ko) 2003-03-20
IL153514A (en) 2008-08-07
EP1294361A2 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
IL153514A0 (en) Compositions and methods to improve the oral absorption of antimicrobial agents
ATE238365T1 (de) Wässrige reaktive spachtelmassen (ii)
PL366068A1 (pl) Podstawione indole, środki farmaceutyczne zawierające takie indole i ich zastosowanie jako środków wiążących PPAR-
HUP0301745A3 (en) Cyclopentanoindoles, compositions containing such compounds and their use
CA2225808A1 (en) Silver-based pharmaceutical compositions
IL160713A0 (en) Compositions containing oxyntomodulin for prevention or treatment of excess weight
AU3701100A (en) Deodorant compositions containing cyclodextrin odor controlling agents
BR9917282A (pt) Composição oral para inibição de mal odor oral
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
DK0901366T3 (da) Tandplejemiddel mod tandstendannelse indholdende letopløseligt pyrophosphat
WO2002053116A3 (en) Dual component dentifrice for reducing mouth odors
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
GB0223837D0 (en) Improvements in and to organic compositions
WO1999062985A3 (en) A polymer composition comprising natural stabilizers
DE69909623D1 (de) Geruchsabsorber
MXPA03000606A (es) Derivados de benzofurano y su uso como agentes antibacterianos.
ATE239779T1 (de) Bleichmittelzusammensetzungen
PL340459A1 (en) Agonists of 5ht1f
WO2004034961A3 (en) Antimicrobial agents and uses thereof
WO2002045620A3 (en) Antimicrobial wipe
GB0100643D0 (en) Liquid antimicrobial compositions
AU1867300A (en) An aqueous iodine containing disinfectant composition
DE69933463D1 (de) Spray mit amphoterer zusammensetzung zur reduzierung von gerüchen
AU2002210646A1 (en) Use of 1,3-diphenylpropane derivatives as active principles in cosmetic compositions for inhibiting body odours
WO2004112843A3 (en) Odor control compositions and methods

Legal Events

Date Code Title Description
RECP Rectifications of patent specification